Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its BTK inhibitor BRUKINSA® (zanubrutinib) and non-clinical data on its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and four posters at the 62nd American Society for Hematology (ASH) Annual Meeting, taking place virtually on December 5-8, 2020.

BeiGene is co-sponsoring a satellite symposium entitled Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes, to be held on Friday, December 4 at 3:00 p.m. PT; registration for the symposium can be accessed at https://events.clinicaloptions.com/oncology/event-list/event/?id=a95f3d53-49d8-ea11-80f9-005056943d50.

Oral Presentation:

Title:

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Publication #:

339

Session Title:

623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia

Date and Time:

Sunday, December 6, 2020 at 10:15 a.m. PT

Presenter:

Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Australia

Poster Presentations:

Title:

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial

Publication #:

2940

Session Title:

623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Date:

Monday, December 7, 2020 at 7:00 a.m. PT

Presenter:

Gang An, M.D., Ph.D., Chinese Academy of Medical Sciences, Blood Diseases Hospital, China

Title:

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Publication #:

2947

Session Title:

623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III

Date:

Monday, December 7, 2020 at 7:00 a.m. PT

Presenter:

Mazyar Shadman, M.D., MPH, Fred Hutchinson Cancer Research Center, University of Washington

Title:

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Publication #:

1306

Session Title:

642. CLL: Therapy, excluding Transplantation: Poster I

Date:

Saturday, December 5, 2020 at 7:00 a.m. PT

Presenter:

Jennifer R. Brown, M.D., Ph.D., Dana-Farber Cancer Institute

Title:

Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Publication #:

1116

Session Title:

622. Lymphoma Biology—Non-Genetic Studies: Poster I

Date:

Saturday, December 5, 2020 at 7:00 a.m. PT

Presenter:

Yuqin Song, M.D., Ph.D., Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), China

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

Contacts:

Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.